Evidence map›Paper›PMID 39076747›Full record

ReviewReviews in cardiovascular medicine2023

Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know.

Armando Ferrera, Vincenzo Fiorentini, Simone Reale, Giorgio Solfanelli, Giacomo Tini, Emanuele Barbato, Massimo Volpe, Allegra Battistoni

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Reviews in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Armando FerreraClinical and Molecular Medicine Department, Sapienza University of Rome, 00198 Rome, Italy.
Vincenzo FiorentiniClinical and Molecular Medicine Department, Sapienza University of Rome, 00198 Rome, Italy.
Simone RealeClinical and Molecular Medicine Department, Sapienza University of Rome, 00198 Rome, Italy.
Giorgio SolfanelliClinical and Molecular Medicine Department, Sapienza University of Rome, 00198 Rome, Italy.
Giacomo TiniClinical and Molecular Medicine Department, Sapienza University of Rome, 00198 Rome, Italy.
Emanuele BarbatoClinical and Molecular Medicine Department, Sapienza University of Rome, 00198 Rome, Italy.
Massimo VolpeClinical and Molecular Medicine Department, Sapienza University of Rome, 00198 Rome, Italy.
Allegra BattistoniClinical and Molecular Medicine Department, Sapienza University of Rome, 00198 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapies have changed the prognosis of patients affected by cancer over the last 20 years, with a significant increase in survival rates. However, they can cause serious adverse effects that may limit their use. In particular, anthracyclines, widely used to treat both hematologic cancers and solid cancers, may cause cardiac toxicity, leading to the development of heart failure in some cases. This review aims to explore current evidence with regards to anthracyclines' cardiotoxicity, with particular focus on the classifications and underlying molecular mechanisms, in order to provide an overview on the current methods of its diagnosis, treatment, and prevention. An attentive approach and a prompt management of patients undergoing treatment with anthracyclines is imperative to avoid preventable antineoplastic drug discontinuation and is conducive to improving both short-term and long-term cardiovascular morbidity and mortality.

Indexed as

anthracyclinesanthracyclines-induced cardiotoxicitycardio-oncologycardiotoxicitychemotherapydrug-induced heart failure

Identifiers

PMID39076747
PMCPMC11273047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.